The First mRNA Flu Vaccine Could Change the 2026–27 Flu Season

 The First mRNA Flu Vaccine Could Change the 2026–27 Flu Season

The flu vaccine landscape is entering a new era. The U.S. Food and Drug Administration (FDA) has approved mFlusiva, Moderna’s first mRNA-based seasonal influenza vaccine, marking the first FDA-approved mRNA vaccine specifically designed to prevent seasonal flu. The vaccine is approved for adults aged 50 and older, with traditional approval for people ages 50–64 and accelerated approval for those 65 and above.

What Is mFlusiva?

mFlusiva, also known as mRNA-1010, uses the same basic mRNA technology that made the Moderna COVID-19 vaccines possible.

Instead of putting an influenza protein directly into the body, the vaccine delivers messenger RNA instructions to cells. These instructions tell cells to temporarily produce influenza hemagglutinin (HA) proteins. The immune system then recognizes these proteins and develops an immune response that can help protect against influenza infection.

The mRNA itself does not change a person's DNA. It provides temporary instructions that are used by cells to make the targeted antigen before the mRNA is broken down.

Why Could mRNA Technology Matter for Flu?

Seasonal influenza viruses change continuously. Traditional flu vaccines require months of manufacturing, including processes that can involve growing viruses in eggs or cell cultures.

One potential advantage of mRNA technology is speed. Because the vaccine's genetic instructions can be redesigned more rapidly, manufacturers may eventually be able to respond more quickly when circulating influenza strains change.

That could help improve the match between a vaccine and the viruses circulating during a particular flu season.

How Effective Was mFlusiva?

The FDA approval was supported by a large Phase 3 trial involving more than 40,000 adults aged 50 and older.

In the study, approximately 2% of participants who received mFlusiva developed influenza compared with about 2.8% of those receiving a standard-dose flu vaccine. Overall, mFlusiva demonstrated approximately 26.6% greater relative efficacy against influenza than the standard-dose comparator.

The vaccine also generated strong immune responses in older adults. However, additional research is being conducted to confirm its clinical benefit compared with enhanced influenza vaccines in people aged 65 and older.

What About Side Effects?

The safety profile observed in clinical trials was generally consistent with what is commonly seen after vaccination.

Reported reactions included:

Pain at the injection site

Fatigue

Headache

Muscle or joint aches

Fever

Most reactions were temporary and mild to moderate.

Who Can Get mFlusiva?

At the time of FDA approval, mFlusiva is authorized for adults aged 50 years and older.

For adults 50–64, the FDA granted traditional approval. For adults 65 and older, the vaccine received accelerated approval, with additional studies required to confirm clinical benefit in this age group.

Availability during the 2026–27 influenza season may vary because influenza vaccine purchasing and contracting decisions were already underway before the approval.

Does This Mean Traditional Flu Vaccines Are No Longer Needed?

No.

Traditional influenza vaccines remain important tools for preventing flu. The arrival of mFlusiva adds another option rather than immediately replacing existing vaccines.

Experts continue to emphasize that people who are recommended to receive influenza vaccination should not necessarily delay vaccination simply while waiting for the newest technology to become available.

What Could the Future Look Like?

The approval of mFlusiva could be important beyond the 2026–27 flu season.

If mRNA technology can consistently provide strong protection while allowing faster vaccine production and strain updates, it could change how seasonal influenza vaccines are developed.

The platform could also support future combination vaccines, including potential vaccines targeting both influenza and COVID-19.

For now, however, researchers and regulators will continue collecting real-world data to determine how mFlusiva performs across different age groups and influenza seasons.

The Bottom Line

mFlusiva represents a major milestone in influenza vaccination. It is the first FDA-approved mRNA vaccine for seasonal flu and brings the technology used in COVID-19 vaccines into another major infectious-disease prevention program.

Its potential advantages include rapid vaccine development, strong immune responses and the possibility of adapting more quickly to changing influenza viruses. But continued surveillance and clinical research will determine how much of an advantage mRNA technology ultimately provides over established flu vaccines.

As the 2026–27 flu season approaches, mFlusiva could mark the beginning of a new chapter in the fight against seasonal influenza.